A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rati...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Janet K., Liranso, Tesfaye, Saylor, Keith, Tulloch, Gabriela, Adewole, Toyin, Schwabe, Stefan, Nasser, Azmi, Findling, Robert L., Newcorn, Jeffrey H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939319/
https://www.ncbi.nlm.nih.gov/pubmed/30924702
http://dx.doi.org/10.1177/1087054719836159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939319/
https://www.ncbi.nlm.nih.gov/pubmed/30924702
http://dx.doi.org/10.1177/1087054719836159

Ejemplares similares